All Posts
Review | Evaluation and management of hypernatremia in adults
30 Mar, 2023 | 14:20h | UTC
Improving cascade outcomes for active TB | A global systematic review and meta-analysis of TB interventions
30 Mar, 2023 | 14:17h | UTC
2ry analysis of a RCT | Vitamin D supplementation does not affect cognitive function in older adults
30 Mar, 2023 | 14:14h | UTCVitamin D supplementation and cognition—Results from analyses of the D-Health trial – Journal of the American Geriatrics Society (link to abstract – $ for full-text)
Related:
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Research: Circulating vitamin D concentration and risk of seven cancers
Research: Vitamin D and risk of total and site specific cancers
RCT | Ganitumab added to chemotherapy did not improve outcomes in patients with metastatic Ewing sarcoma
30 Mar, 2023 | 14:16h | UTCRandomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children’s Oncology Group – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Ganitumab Provides No Benefit in Metastatic Ewing Sarcoma – Cancer Therapy Advisor
Prematurity and bronchopulmonary dysplasia: what general pediatricians should know
30 Mar, 2023 | 14:12h | UTCPrematurity and BPD: what general pediatricians should know – European Journal of Pediatrics
RCT | Hydroxychloroquine in children with proliferative lupus nephritis
30 Mar, 2023 | 14:11h | UTC
Phase 2 RCT | Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes
30 Mar, 2023 | 14:08h | UTCSafety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Update on the management of acute pancreatitis
30 Mar, 2023 | 14:10h | UTCUpdate on the management of acute pancreatitis – Current Opinion in Critical Care
Related:
Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis – New England Journal of Medicine
Acute Pancreatitis: Diagnosis and Treatment – Drugs
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
Research: Endoscopic or Surgical Step-up Approach for Infected Necrotising Pancreatitis
Evidence-Based Approach to the Surgical Management of Acute Pancreatitis – The Surgery Journal
RCT | Efficacy and safety of colesevelam for the treatment of bile acid diarrhea
30 Mar, 2023 | 14:06h | UTCEfficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Borup et al – Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo controlled, phase 4 clinical trialhttps://t.co/m1r0heRgjX#gitwitter #BAD #diarrhoea pic.twitter.com/zk1TnZFS6b
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) February 7, 2023
Review | Multi-modality cardiac imaging evaluation of infective endocarditis
30 Mar, 2023 | 14:05h | UTCContemporary Review of Multi-Modality Cardiac Imaging Evaluation of Infective Endocarditis – Life
SR | Consequences of Shigella infection in young children
30 Mar, 2023 | 13:52h | UTC
Brief Review | Acute mesenteric ischemia
30 Mar, 2023 | 13:44h | UTCAcute mesenteric ischaemia – British Journal of Surgery
Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
30 Mar, 2023 | 13:49h | UTC
Review | Insomnia diagnosis and treatment across the lifespan
30 Mar, 2023 | 13:36h | UTCInsomnia diagnosis and treatment across the lifespan – Journal of Family Practice
SR | Extracutaneous features and complications of the Ehlers-Danlos syndromes
30 Mar, 2023 | 13:41h | UTC
Ketamine misuse: an update for primary care
30 Mar, 2023 | 13:34h | UTCKetamine misuse: an update for primary care – British Journal of General Practice
Review | How to integrate shared decision-making into your practice
30 Mar, 2023 | 13:35h | UTCHow to integrate shared decision-making into your practice – Journal of Family Practice
M-A | Incidence of multiple organ failure in adult polytrauma patients
30 Mar, 2023 | 13:30h | UTC
Ear wax management in primary care: what the busy GP needs to know
30 Mar, 2023 | 13:33h | UTC
Study shows a slight breast cancer risk increase with progestogen-only birth control, comparable to combined oral methods
29 Mar, 2023 | 13:35h | UTCSummary: A UK study and meta-analysis examined breast cancer risk linked to hormonal contraceptives, emphasizing progestagen-only contraceptives in premenopausal women. Utilizing a nested case-control design with the Clinical Practice Research Datalink (CPRD), a primary care database, the study included 9,498 women under 50 diagnosed with invasive breast cancer between 1996 and 2017, and 18,171 closely matched controls. The meta-analysis merged CPRD findings with 12 observational studies on progestagen-only preparations.
The results revealed that current or recent use of combined oral contraceptives, oral progestagen-only contraceptives, injectable progestagen, and progestagen intrauterine devices all led to a similar increase in breast cancer risk. The 15-year absolute excess risk associated with five years of oral combined or progestagen-only contraceptive use ranged from 8 per 100,000 users aged 16-20 to 265 per 100,000 users aged 35-39. The study concluded that both contraceptive types were linked to a slight breast cancer risk increase, and these risks must be weighed against the benefits of contraceptive use during childbearing years.
News Release: Study finds similar association of progestogen-only and combined hormonal contraceptives with breast cancer risk – PLOS
M-A | Limited evidence for analgesic effectiveness in acute low back pain treatment
29 Mar, 2023 | 13:32h | UTCSummary: The objective of this systematic review and network meta-analysis was to assess the effectiveness and safety of various analgesic medicines for treating acute non-specific low back pain. After examining 98 randomized controlled trials with over 15,000 participants, the study found that the quality of evidence for the effectiveness and safety of these medications is low or very low.
Some analgesic medicines showed potential in reducing pain intensity, but the evidence was limited due to trial risk of bias and imprecision in effect estimates. Furthermore, certain medications might increase the risk of adverse events during treatment, with evidence ranging from moderate to very low confidence.
Given the lack of high-quality evidence, clinicians and patients are advised to be cautious when using analgesic medicines for acute non-specific low back pain. More robust head-to-head comparison trials are needed to provide clearer guidance on the best course of treatment.
News Release: Study finds “considerable uncertainty” around effectiveness and safety of analgesics for low back pain – BMJ Newsroom
Commentary from the author on Twitter (thread – click for more)
Out today in @bmj_latest.
We found “considerable uncertainty” around the effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain.
Available at https://t.co/PeOmEOeJyJ
Thread 🧵 pic.twitter.com/T8YDNGhhME
— Michael Wewege, PhD (@mawewege) March 22, 2023
Review | Cerebrovascular manifestations of SARS-CoV-2
29 Mar, 2023 | 13:29h | UTC
Alcohol minimum unit pricing in Scotland led to substantial decrease in alcohol-attributable deaths and hospitalizations
29 Mar, 2023 | 13:28h | UTCNews Release: Minimum unit pricing for alcohol associated with a 13% decrease in deaths from alcohol consumption in Scotland – Lancet
Commentaries:
Minimum pricing averts alcohol deaths, study claims – BBC
Scotland’s minimum pricing linked to 13% drop in alcohol-related deaths, study finds – The Guardian
Commentary on Twitter (thread – click for more)
Minimum unit pricing for #alcohol was introduced in Scotland in 2018 (50p per unit) with the aim of reducing alcohol consumption in the heaviest drinkers.
A new study analyses the impact of the policy on alcohol-specific hospitalisations and deaths. https://t.co/ehoHjbc8lw
— The Lancet (@TheLancet) March 21, 2023
M-A | Aggressive IV hydration may increase mortality risk in severe acute pancreatitis
29 Mar, 2023 | 13:26h | UTCSummary: This systematic review and meta-analysis investigated the outcomes of aggressive and non-aggressive intravenous hydration in patients with severe and non-severe acute pancreatitis (AP). The study included nine randomized controlled trials with a total of 953 participants.
The findings revealed that aggressive intravenous hydration significantly increased mortality risk in severe AP cases, and fluid-related complication risk in both severe and non-severe AP cases. However, the study has some limitations, as only one study with 249 participants was judged to have a low risk of bias in all domains, while the remaining eight studies had non-low risk of bias, raising concerns about the reliability of the findings.
Despite these concerns, the findings still suggest that more conservative intravenous fluid resuscitation protocols for AP may be preferable. Further research with more rigorous study designs is needed to provide robust evidence on the effectiveness of different intravenous hydration strategies in treating acute pancreatitis.
Review | Recompensation in cirrhosis: current evidence and future directions
29 Mar, 2023 | 13:24h | UTCRecompensation in Cirrhosis: Current Evidence and Future Directions – Journal of Clinical and Experimental Hepatology (free for a limited period)